SARS-COV-2 Seroprevalence and Seroconversion Among Employees of the Universitair Ziekenhuis Brussel During the 2020 COVID-19 Outbreak (COVEMUZ)

U

Universitair Ziekenhuis Brussel

Status

Unknown

Conditions

Sars-CoV2

Treatments

Diagnostic Test: Serological testing

Study type

Interventional

Funder types

Other

Identifiers

NCT04426292
COVEMUZ

Details and patient eligibility

About

A novel zoonotic coronavirus was discovered in Wuhan (Hubei Province, China) mid-December 2019 and was named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The virus rapidly spread to the rest of the world, including Europe and explicitly affects the respiratory system, generating Coronavirus disease 2019 (COVID-19). This study is a monocentric interventional prospective cohort study. After signing a written informed consent, participants will be recruited for questionnaire completion and blood sampling. Sample storage and analysis will be performed at the laboratory of microbiology of the UZ Brussel. * To document SARS-CoV-2 seroprevalence among employees of the UZ Brussel at day 0 (i.e. at beginning of the study, planned early May 2020), month 2 and month 5. * To document number of SARS-CoV-2 seroconversions among employees of the UZ Brussel over a period of 5 months.

Enrollment

3,500 estimated patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Any adult employee of the UZ Brussel who provided a signed informed consent to participate in the study.

Exclusion criteria

  • UZ Brussel employees whose contract expires within 6 months of study initiation, with the exception of resident trainees (if training continues in another hospital, resident trainees will be asked to perform the last sampling when leaving the UZ Brussel).
  • Staff not active during the inclusion period

Trial design

Primary purpose

Health Services Research

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

3,500 participants in 1 patient group

General arm
Other group
Description:
All patients follow this arm. Patients will undergo 3 blood sample testings at 3 different time points and have to fill in a questionnaire at 3 different time points
Treatment:
Diagnostic Test: Serological testing

Trial contacts and locations

1

Loading...

Central trial contact

Sabine Allard, MD; Laurien De Greef, Nurse

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems